about
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerThe mutational landscape of prostate cancerDNA Repair in Prostate Cancer: Biology and Clinical ImplicationsUnraveling the clonal hierarchy of somatic genomic aberrations.Recurrent prostate cancer genomic alterations predict response to brachytherapy treatmentNext-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.Evidence for molecular differences in prostate cancer between African American and Caucasian menThe DNA binding activity of p53 displays reaction-diffusion kinetics.Genomic rearrangements in prostate cancer.SPOP mutation leads to genomic instability in prostate cancer.Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.Punctuated evolution of prostate cancer genomes.Lethal Prostate Cancer in the PLCO Cancer Screening Trial.DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis.TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.SPOP mutations in prostate cancer across demographically diverse patient cohorts.Ureteroileal anastomosis with intraluminal visualization: technique and outcomes.Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.The prostate cancer genome: perspectives and potential.Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.Reprint of: The prostate cancer genome: Perspectives and potential.Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.Molecular subtyping of prostate cancer.Clinical variability and molecular heterogeneity in prostate cancer.The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial.Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men.Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis.Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium.Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway.Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrationsEfficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial.Evolution of novel biomarkers for detection of prostate cancer.Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456.
P50
Q24616117-3843E592-DF4E-4677-BFB8-7B7839246FADQ26851631-0424B19B-7054-4C6D-B32B-B058790CA56DQ28079127-B282ABBB-FE03-4BE3-8954-E219BDA781D3Q30587156-EFBB32CE-E408-449F-8A4E-54E1F8F26923Q33852664-56EC8644-2153-423C-B741-F4E5FFD9613EQ34007950-BDE802CA-47D1-481D-8883-9B34A00197ACQ34205227-3D5A48B6-09D9-4216-AEB9-3AD94A823A45Q34680338-3FB16C34-0F8C-4B67-8859-AD93FCD6FD06Q34722101-B17EF116-078C-48C4-975E-560E394D2BC1Q36210354-9A9E4693-A45A-4517-81A9-D64532F9BEBFQ36799180-36D3C54A-C464-4D35-BCEA-75ECFBC9EC5BQ36950514-CA9520E1-712F-47F1-8359-EBA6F619C731Q37008842-2D627619-E2CF-4A21-A841-B11FA5C81280Q37212795-2C958ED0-4003-4D3C-9B64-6C791091744BQ37460447-D165778D-C4FA-4C82-BEE3-C00E59191FCAQ37584305-124CF568-D62E-4912-A720-03AEC7579CCFQ37728527-DA127D57-BAD3-4C28-9A9C-7360119F96CDQ37972706-8490ECB4-8D20-4179-8DC4-5084677EA77DQ38163225-C3246EDE-BAFB-44CF-A5A6-C5B83C085F5CQ38216021-B581DEA0-A6BA-4FF8-A2BB-259D7EE1A1C1Q38264014-95BD01BA-BFAE-45A7-9521-1DE292EBB75FQ38366212-462EDC36-19C0-49DE-83EA-0A04CA937075Q38733910-711ED264-02DA-416F-9B1F-52E34F4618F5Q38778266-0FC6CC1F-7345-4A4E-8D5D-519824647745Q38808811-B03EE38B-CBBA-404E-AEFC-A81CAF141D34Q38827251-B78E17ED-47A2-4709-B17B-88EBDA768D6AQ39003646-8619D6F7-A8C1-43B0-9B71-407A8277D0F0Q39194232-9798CCC4-CD6B-46DD-A33B-3FC41A60CD31Q39469006-08E270C0-501C-4B5E-8FF9-ADDF448A5723Q39536821-AEBC652D-A726-422C-913D-07920A9F5099Q40248545-678A5290-5435-4438-834C-4709D1E74053Q40365385-2E177A1F-CF8B-46E9-8377-7EC4B3C1A122Q40444115-7BA66A64-2760-49E5-B32A-706E685800D5Q40626867-0C04D94D-4C12-4236-9883-FA86667B0F63Q40642898-1874DB48-5BE9-4A5F-B5E7-07DD3A716CB5Q42356508-A8A5EE61-1C73-4E0D-8FFE-D00A2743A22FQ44373257-EE047157-C8E3-4D8A-B5AF-1C2C0215CC3DQ45360077-5E7B793C-DFB8-4F94-B250-A142FFCA15C4Q47956436-D05A02BB-EDC6-4B42-AF82-1412AE9E65D3Q50943467-65FC1EA5-8756-47FD-99E5-F94A95C07B3C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christopher E. Barbieri
@ast
Christopher E. Barbieri
@en
Christopher E. Barbieri
@es
Christopher E. Barbieri
@nl
Christopher E. Barbieri
@sl
type
label
Christopher E. Barbieri
@ast
Christopher E. Barbieri
@en
Christopher E. Barbieri
@es
Christopher E. Barbieri
@nl
Christopher E. Barbieri
@sl
prefLabel
Christopher E. Barbieri
@ast
Christopher E. Barbieri
@en
Christopher E. Barbieri
@es
Christopher E. Barbieri
@nl
Christopher E. Barbieri
@sl
P106
P1153
7103147392
P21
P31
P496
0000-0002-0381-1947